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Abstract
Objectives To determine the effects of adding an oxytocin infusion to
bolus oxytocin on blood loss at elective caesarean section.
Design Double blind, placebo controlled, randomised trial, conducted
from February 2008 to June 2010.
Setting Five maternity hospitals in the Republic of Ireland.
Participants 2069 women booked for elective caesarean section at
term with a singleton pregnancy. We excluded women with placenta
praevia, thrombocytopenia, coagulopathies, previous major obstetric
haemorrhage (>1000 mL), or known fibroids; women receiving
anticoagulant treatment; those who did not understand English; and
those who were younger than 18 years.
Intervention Intervention group: intravenous slow 5 IU oxytocin bolus
over 1 minute and additional 40 IU oxytocin infusion in 500 mL of 0.9%
saline solution over 4 hours (bolus and infusion). Placebo group: 5 IU
oxytocin bolus over 1 minute and 500 mL of 0.9% saline solution over
4 hours (placebo infusion) (bolus only).
Main outcomes Major obstetric haemorrhage (blood loss >1000 mL)
and need for an additional uterotonic agent.
Results We found no difference in the occurrence of major obstetric
haemorrhage between the groups (bolus and infusion 15.7% (158/1007)
v bolus only 16.0% (159/994), adjusted odds ratio 0.98, 95% confidence
intervals 0.77 to 1.25, P=0.86). The need for an additional uterotonic
agent in the bolus and infusion group was lower than that in the bolus
only group (12.2% (126/1033) v 18.4% (189/1025), 0.61, 0.48 to 0.78,
P<0.001). Women were less likely to have a major obstetric haemorrhage
in the bolus and infusion group than in the bolus only group if the
obstetrician was junior rather than senior (0.57, 0.35 to 0.92, P=0.02).
Conclusion The addition of an oxytocin infusion after caesarean delivery
reduces the need for additional uterotonic agents but does not affect the
overall occurrence of major obstetric haemorrhage.
Trial Registration Current Controlled Trials ISRCTN17813715.
Introduction
Caesareansectionisoneofthemostcommonlyperformedmajor
operations in women throughout the world. These operations
have escalated over the past four decades to between 20% and
30% in most developed countries, up to 40% in China, and as
high as 70% in some Latin American countries.
1-3 Operative
morbidityincludeshaemorrhage,anaemia,risksoftransfusion,
hysterectomy, and in severe cases, maternal death.
4 Obstetric
haemorrhage is the leading cause of maternal mortality
worldwide, and in most cases it relates to uterine atony.
Although the value of routine oxytocics to reduce postpartum
haemorrhageaftervaginalbirthhasbeenwellestablished,their
value in caesarean section has received little attention.
5 It has
beenassumedthatthebenefitsofoxytocicsobservedatvaginal
birth also apply to caesarean section.
6 7 The guidelines of the
Royal College of Obstetricians and Gynaecologists (UK) on
caesarean section recommend a slow intravenous bolus dose of
5 IU of oxytocin after delivery of the infant.
8 This dose is based
on the principles of active management of the third stage of
labour
9 10 and is consistent with practice across most of Europe
and Australia.
11 In a survey of obstetricians and anaesthetists in
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Research
RESEARCHthe UK, the use of an oxytocin bolus was standard treatment,
although the dose varied between 5 IU and 10 IU.
12 In settings
whereanoxytocinbolusisusedroutinely,anadditionalinfusion
of oxytocin may be required if haemorrhage occurs. This
practicehasledsomeobstetricianstouseanadditionalinfusion
of oxytocin on a selective or routine basis for high risk cases,
despite a lack of evidence to support this practice.
12 13
By contrast, an alternative practice in the United States
recommends the use of an oxytocin infusion instead of a bolus
dose. This approach may reflect concerns about the
physiological effects of bolus oxytocin.
14 Intravenous oxytocin
has a short half life (4-10 minutes); therefore the potential
advantage of an oxytocin infusion at caesarean section is in
maintaining uterine contractility throughout the surgical
procedureandimmediatepostpartumperiod,whenmostprimary
haemorrhageoccurs.Variousneweruterotonicagentshavebeen
evaluated,
15-20 and the recent Canadian guidelines recommend
the use of carbetocin (a long acting synthetic oxytocic) instead
of oxytocin at caesarean section.
21 However, carbetocin is
expensiveandwouldnotbeavailableinsettingswhereresources
are scarce.
We aimed to compare a standard 5 IU bolus of oxytocin and an
additional 40 IU oxytocin infusion (bolus and infusion) with a
5 IU bolus of oxytocin and placebo infusion (bolus only), to
determine whether use of an inexpensive and widely used drug
can further improve prevention of haemorrhage at caesarean
section.Wepostulatedthataroutineadditionaloxytocininfusion
would reduce either the occurrence of major obstetric
haemorrhage or the use of an additional uterotonic agent by
preventing uterine atony.
Methods
TheElectiveCaesareanSectionSyntocinon(oxytocin)Infusion
Trial (ECSSIT) was a double blind, placebo controlled,
randomised study.
Population
The study population included healthy women at term (>36
weeks)withsingletonpregnanciesbookedforelectivecaesarean
section. We excluded women with placenta praevia,
thrombocytopenia, coagulopathies, previous major obstetric
haemorrhage (>1000 mL), known fibroids, or women who
received anticoagulant treatment. We also excluded women
who did not understand English or were younger than 18 years.
Clinicians could exclude additional patients at their discretion
if they expected major haemorrhage, in keeping with the
recommendations of the research ethics committee.
Intervention and comparison
We compared oxytocin bolus 5 IU and oxytocin infusion (40
IU oxytocin in 500 mL saline infused over four hours) with 5
IU oxytocin bolus and placebo infusion (500 mL saline infused
over 4 hours).
Outcomes
Primary outcomes
There were two primary outcomes, both of which were binary:
majorobstetrichaemorrhageanduseofanadditionaluterotonic
agent. We defined major obstetric haemorrhage as calculated
blood loss of more than 1000 mL. This estimate was based on
the difference between the preoperative and postoperative
packed cell volume (PCV), and is calculated as follows:
22 23
Calculated estimated blood loss = estimated blood
volume × (preoperative PCV − postoperative
PCV)/preoperative PCV
(whereestimatedbloodvolume=bookingweight(kg)
× 85)
We chose this calculation as a quantitative objective measure
to estimate haemorrhage because it is widely accepted that
cliniciansunderestimatebloodlossandthatgravimetricmethods
includeliquorinadditiontoblood,whichlimitsaccuracy.
24We
chose the use of an additional uterotonic agent as a primary
outcome because obstetricians are likely to intervene in the
event of uterine atony and use an additional agent to prevent
haemorrhage.
Secondary outcomes
Weassessedbloodlossgravimetricallybymeasuringthesuction
volume and swab weight to establish a “measured” blood loss.
We used disposable waterproof drapes with pockets that
captured blood and liquor. Although this approach is subject to
technicalandobservererror,itisconsideredmoreaccuratethan
clinicians’ subjective estimations of blood loss. Additionally,
routine preoperative and postoperative measurement of packed
cellvolumeisnotperformedinmanycountries.Othersecondary
outcomes included: change in haemoglobin and packed cell
volume; severe anaemia 48 hours after delivery (reduction in
haemoglobin ≥20%); need for blood transfusion; side effects
(including vomiting and hypotension); and postnatal length of
stay in theatre or recovery and in hospital.
Trial procedures
We undertook an initial pilot study to inform the design of the
main trial, the recruitment procedures, and the sample size
calculation.
25Werecruitedwomenfromfouruniversityteaching
hospitals and one private hospital in the Republic of Ireland
between February 2008 and June 2010. Eligible women were
approachedandofferedstudyinformationatthetimeofbooking
forelectivecaesareansection.Onthedayofsurgery,thewomen
confirmedparticipationandcompletedinformedwrittenconsent.
Randomisation took place after patients consented to
participation in the study. We used an automated web based
randomisation system ensuring allocation concealment.
Allocation was stratified by centre and previous caesarean
section(no/yes),andblockedbyuseofrandompermutedblocks
ofvaryingsize.Werandomlyassignedwomentoreceiveeither
an intravenous slow bolus of oxytocin 5 IU over 1 minute and
40 IU oxytocin in 500 mL of 0.9% saline solution over 4 hours
(bolus and infusion), or an oxytocin bolus 5 IU over 1 minute
and 500 mL of 0.9% saline solution over 4 hours (bolus only).
A clinically trained researcher (midwife or obstetric research
fellow) prepared the active and placebo infusions away from
thetheatre.Thisprocessensuredtheblindingofeveryoneexcept
for this individual, who then had no subsequent role in patient
management or outcome assessment.
We defined the grade of obstetrician or anaesthetist as junior
andsenior,withajuniorindividualhavinghadspecialisttraining
forthreeyearsorless.Surgicalandanaesthetictechniqueswere
standardised, with all patients undergoing spinal anaesthesia.
Patients received an intravenous bolus of 500 mL crystalloid
before spinal anaesthesia. Anaesthetists replaced blood loss at
operationwithcolloidinfusionorbloodwhendeemednecessary.
Intravenous crystalloids were continued at 1 L every 8 hours
until the morning after surgery, unless the patient was unable
totolerateoralfluids.Surgeonsoperatedtoastandardprocedure
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RESEARCHthatspecifiedcontrolledcordtractionfordeliveryoftheplacenta
after administration of the oxytocin bolus, two layer closure of
the uterine incision, and to avoid delivering the uterus for
suturingunlessclinicallyindicated.Iftheuterusremainedatonic
despite the trial intervention, the obstetrician or anaesthetist
could use an additional uterotonic agent by replacing the trial
infusion with a known oxytocin infusion or by using other
additional agents (or both). We recorded deviations from these
standard procedures. The published trial protocol provides
further details.
26
Thetrialsteeringcommitteemetquarterly.Anindependentdata
monitoring committee reviewed recruitment and safety data
after recruitment of 1000 patients.
We received institutional ethics approval and maternal written
consent.
Statistical analysis
We estimated from our pilot study that around 14% of study
participants in the bolus only group would have a blood loss of
greater than 1000 mL, and that a relative reduction of 20-50%
would be feasible and clinically important.
25 With an estimated
incidence in the bolus only group of 14%, 80% power, and 5%
two sided α, a total number for analysis of 1000 participants
per group would be required to detect a between group
difference of 4.2 percentage points, equivalent to an odds ratio
of 0.67. We inflated the target sample size to be recruited, to
allow for a 3% margin of missing primary outcome data (for
example, blood test not performed or at the wrong time point).
Analysis was by intention to treat.
Weevaluatedthesuccessofblindingwithinasubsampleof109
recruited patients by asking patients, obstetricians, and
anaesthetists to identify the infusion (327 responses). Our
analysis used Cohen’s κ coefficient, which examines the level
ofagreementbeyondthatexpectedbychance.Agreementranges
from“<0”,implyingnoagreement,to“>0.81”,indicatingalmost
perfect agreement. All analyses were blinded to treatment
allocation using SPSS 16 and Stata 11.
We used descriptive statistics to assess comparability of the
trialgroupsatbaseline.Theprimarybetweengroupcomparisons
for both primary (binary) outcomes used multivariable logistic
regression models with adjustment for stratification variables.
We then investigated the effects on the primary analyses of
further adjustment for any variables displaying a noticeable
imbalance between the groups at baseline. We analysed
secondary outcomes in a similar way using regression models
(logistic or linear) depending on outcome type. Results from
all regression models are presented as point estimates (odds
ratios or differences in means), 95% confidence intervals, and
P values. Finally we conducted a series of planned subgroup
analyses by including appropriate interaction terms in the
regressionmodelstoascertainanydifferentialeffectsinrelation
to operator experience (junior or senior grade), choice of
anaesthetic(adherenceornon-adherencetoprotocol),andrepeat
caesarean section (0, 1, ≥2).
26
Results
Study population
We enrolled 2069 women, of whom 2058 were suitable for
inclusion (1025 bolus only, 1033 bolus and infusion). We
deemed 11 women to be ineligible after randomisation because
their caesarean sections were cancelled. Participant flow is
shown in figure 1. Patients were followed up until hospital
discharge.
Descriptive statistics
Table 1 lists characteristics of the trial participants at baseline.
The mean age of women at delivery was 33.2 years, the median
paritywas1(interquartilerange1).Ofthe2058eligiblewomen,
712 (34.6%) had no previous caesarean section and 1943
(94.4%) received the intervention as intended. For women who
had preoperative haemoglobin concentrations recorded, the
occurrence of preoperative anaemia (haemoglobin <105.0 g/L)
was high (14.7% (302/2053)). Junior obstetricians performed
42.1% (866/2058) of the caesarean sections. Women and
clinicians were successfully blinded to treatment allocation,
with neither group able to identify the trial infusion with any
accuracy beyond chance (overall 207 did not know, 62 were
correct, 47 were incorrect, 11 had no response; κ=0.15).
Primary outcomes
Primary outcome data were collected for 2001 (97%)
participants for major obstetric haemorrhage, and for 2058
(100%)participantsfortheuseofanadditionaluterotonicagent.
Almost one in six women in the study had a major obstetric
haemorrhage, with a similar proportion requiring an additional
uterotonic agent (table 2). There was no difference in major
obstetric haemorrhage between the groups (bolus and infusion
15.7%, 158/1007 v bolus only 16.0%, 159/994, adjusted odds
ratio 0.98, 95% confidence intervals 0.77 to 1.25, P=0.86).
Women in the bolus and infusion group were less likely to
require an additional uterotonic agent than those in the bolus
only group (12.2%, 126/1033 v 18.4%, 189/1025, 0.61, 0.48 to
0.78, P<0.001). A known oxytocin infusion was the most
commonly chosen additional uterotonic agent used (13.4%,
276/2058).Otheruterotonicsusedincludedmisoprostol(4.7%,
96/2058), oxytocin bolus (1.0%, 20/2058),
15-methyl-prostaglandin F2α (0.5%, 10/2058), syntometrine
(0.4%, 8/2058), and ergometrine (0.3%, 7/2058).
Secondary outcomes
We found no difference in any of the secondary outcomes
between the two groups (table 3). Occurrence of postoperative
anaemia(haemoglobin<100.0g/L)andsevereanaemia(≥20%
fall in haemoglobin) were high overall, but did not differ
between the groups. The allocated trial infusion was
discontinued in 216 women (10.5%); 87 (8.4%) in the bolus
and infusion group and 129 (12.6%) in the bolus only group
(P=0.002), mostly for increased bleeding (39%, 84/216) and
uterine atony (36%, 78/216).
Subgroup analyses
Major obstetric haemorrhage occurred more frequently in
women delivered by junior obstetricians than by senior
obstetricians (19.6%, 164/835 v 13.1%, 153/1166). Women
were less likely to have a major obstetric haemorrhage in the
bolus and infusion group than in the bolus only group if the
obstetrician was junior rather than senior (odds ratio 0.57, 95%
confidenceintervals0.35to0.92,P=0.02)(table4).Theeffects
of bolus and infusion on either primary outcome did not differ
for any of the other subgroup variables investigated.
Despitetheimbalanceinadherencetosurgicalprotocolbetween
thetwogroups,itdidnotaffecttheoccurrenceofmajorobstetric
haemorrhage (odds ratio 0.81, 95% confidence intervals 0.46
to 1.44, P=0.48) or the need for an additional uterotonic agent
(1.16, 0.63 to 2.15, P=0.63).
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RESEARCHDiscussion
In this large multicentre trial of women delivered by elective
caesareansection,wefoundthatanoxytocininfusioninaddition
to an oxytocin bolus had no effect on overall occurrence of
major obstetric haemorrhage compared with an oxytocin bolus
and placebo infusion. However, an additional infusion of
oxytocindidreducetheneedforanotheruterotonicagent.Major
obstetric haemorrhage was reduced after use of oxytocin bolus
andoxytocininfusionatcaesareansectionbyjuniorobstetricians
comparedwithseniorobstetricians.Useofanoxytocininfusion
after an initial bolus did not increase the occurrence of side
effects.
Strengths and limitations
We conducted a large pragmatic clinical trial within five
maternity centres in the Republic of Ireland. We defined the
population carefully, with a range of indications for caesarean
section and varying grades of operator. The results are
generalisable to similar populations. Surgical techniques and
anaesthesia were standardised. Data were collected by trained
staffwiththeatrestaffappropriatelytrainedinthemeasurement
of blood loss. Packed cell volumes were checked at 48 hours
afterdeliverytoprovideanadequateintervalforhaemodynamic
equilibrium.
Somelimitationsofourstudywarrantconsideration.Arguably,
weshouldhaveincludedathirdcomparisongroupthatreflected
current US clinical practice—use of a placebo bolus with an
oxytocin infusion (infusion only). However, this additional
group would have required a deviation from hospital protocols
based on recommendations by the Royal College of
ObstetriciansandGynaecologists.
8Althoughweconsideredthis
approach, we thought that it would not have been acceptable in
anyofourrecruitmentcentres,whereoxytocinbolusisstandard
practice.
22 We chose to follow the UK guidelines, basing our
decisiononthebenefitsdescribedinvaginalbirthwhereabolus
dose of oxytocin has a proved role in prevention of postpartum
haemorrhage.
9 10 The mechanisms of action of oxytocin bolus
and infusion are thought to differ; a bolus causes constriction
of the venous sinuses, leading to placental separation and
placentalbedhaemostasis,whereasaninfusionmaintainsuterine
contractility.
We debated the choice of primary outcome and decided on two
outcomes, both reflecting uterine atony. Major obstetric
haemorrhage is the most relevant clinical outcome because it
is a leading cause of maternal death worldwide. However,
clinicians intervene in the event of uterine atony by
administering an additional uterotonic agent. In itself, this
interventionwouldbeanimportantoutcome.Wemeasuredtotal
blood loss at the time of caesarean section but chose a
calculation based estimate, based on preoperative and
postoperative packed cell volume as a primary outcome in the
interestsofobjectivity.Themeasuredbloodlosswouldbemore
relevant in resource poor settings where blood tests are not
routinely performed.
Comparison with existing literature
One trial compared the use of oxytocin bolus and placebo
infusion with oxytocin bolus and 30 IU oxytocin infusion.
27
Data showed reductions in both the use of additional uterotonic
agentsandmajorobstetrichaemorrhage.However,theseresults
are not generalisable because all caesarean sections were
performed in a military hospital setting with routine general
anaesthesia. Regional anaesthetic techniques are standard at
elective caesarean section in developed countries and the use
of general anaesthesia is uncommon. General anaesthesia is
known to increase blood loss at the time of caesarean section
as inhalational agents can reduce uterine contractility and
increase atony.
28 29
Another small trial investigated the effects of a placebo bolus
and oxytocin infusion compared with an oxytocin bolus and
oxytocin infusion, and found no difference in the need for an
additional uterotonic agent in the first 24 hours after caesarean
section.
30 However, this trial is relevant to US practice but not
to European practice and it was limited to patients at high risk
of uterine atony, with neither surgery nor anaesthesia
standardised and blood loss estimated visually. By contrast, we
examined a very large sample of women undergoing elective
caesarean section with regional anaesthesia and our results are
more relevant to the general obstetric population.
Carbetocin is a synthetic oxytocin agonist that has a longer half
life than oxytocin and could be of value. A trial comparing
oxytocin 5 IU bolus versus carbetocin 100 µg showed an
increased use of additional uterotonic agents in the oxytocin
arm.
20 As in our trial, there was no change in mean blood loss
betweenthetwogroups.Thehighcostofcarbetocinwillprevent
its use in countries where resources are scarce and indeed even
in developed countries that implement cost cutting measures.
Clinical implications
Wereportedahighoccurrenceofmajorobstetrichaemorrhage,
greater than that reported in previous studies.
31 32 However, the
different methods of estimating blood loss limits direct
comparisons with other studies.
33 Although estimation of blood
loss at caesarean section can be imprecise, major obstetric
haemorrhageiscommon,eveninwomenwhoseematlowrisk.
This observation leads us to question whether a woman
undergoing an elective caesarean section can ever really be
definedasbeingatlowrisk.Vigilanceinmonitoringbloodloss
and prompt management are essential to avoid the associated
morbidity and mortality.
Although we found a reduction in the use of additional
uterotonic agents, but no change in overall occurrence of major
obstetric haemorrhage with use of oxytocin bolus and infusion,
we did show a reduced occurrence of major obstetric
haemorrhage among inexperienced operators. In our trial, we
had a relatively high proportion of experienced operators
reflecting private practice in Ireland. The proportion of
inexperienced operators will be higher in UK training hospitals
and certainly in parts of the world where access to trained staff
is restricted.
We need to consider how our findings could be implemented.
One approach would be to recommend that all women
undergoingelectivecaesareansectionshouldreceiveanoxytocin
bolus and infusion. This approach would eliminate the need for
clinicaljudgmentonwhentouseanadditionaluterotonicagent.
The potential downside would be that some women would
receiveanunnecessaryinfusion.Alternatively,amoreselective
approach might be to recommend oxytocin infusions at all
elective caesarean sections performed by inexperienced
operators,whosejudgmentofwhentouseadditionaluterotonic
agents may not be as reliable.
While the rates of caesarean section continue to escalate, future
research aimed at reducing major obstetric haemorrhage and
haemorrhagic complications is essential. Previous work has
shown that the risk of major obstetric haemorrhage is greater
atemergencythanatelectivecaesareansection.
31Ourstudywas
limitedtowomenundergoingelectivecaesareansection;future
work should address non-elective deliveries. We are planning
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RESEARCHfurther work on the cost effectiveness of the introduction of an
additional oxytocin infusion at elective caesarean section.
Oxytocin is an inexpensive drug but infusions require either a
4 hour period of monitoring or the use of a controlled infusion
pump. Although 4 hours’ observation after a caesarean section
isinthepatient’sbestinterests,thedelayintransferringpatients
to the postnatal ward affects case throughput. This additional
stepwouldneedtobebalancedwiththeriskofanunrecognised
postpartum haemorrhage occurring on the ward.
Conclusions
Our findings show that the addition of an oxytocin infusion at
elective caesarean section significantly reduces the need for an
additional uterotonic agent, although it does not reduce overall
rates of major obstetric haemorrhage. An oxytocin infusion is
an inexpensive, well tolerated, and relatively safe medication
which, when used routinely, avoids the uncertainty of which
patients should receive an additional uterotonic agent. Our
findings support the use of an additional oxytocin infusion in
terms of reducing major obstetric haemorrhage where the
operator is inexperienced and this approach could be
implemented safely and cheaply into current clinical practice.
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RESEARCHWhat is already known on this topic
Routine use of oxytocin reduces postpartum haemorrhage after vaginal birth, but the effects at caesarean section have
received little attention
What this study adds
Use of an oxytocin bolus and infusion after caesarean delivery reduces the need for additional uterotonic agents but
does not reduce overall occurrence of major obstetric haemorrhage
Side effects were not increased after use of an additional oxytocin infusion
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RESEARCHTables
Table 1| Baseline characteristics and operative variables of trial participants
Bolus only Bolus and infusion
(n=1025, unless stated otherwise) (n=1033, unless stated otherwise)
33.2 (4.9) 33.2 (4.9) Mean maternal age, years (SD)
431 (42.0) 423 (40.9) Maternal age ≥35 years
26.2 (5.0) 26.6 (5.4) Mean BMI (SD)*
338 (33.0) 305 (29.6) Overweight (BMI 25.0-29.9)†
210 (20.5) 241 (23.4) Obese (BMI ≥30.0)†
126 (12.3) 137 (13.3) Chronic medical disorder‡
105 (10.2) 92 (8.9) Cigarette smoker
57 (506) 57 (5.5) Alcohol (moderate/heavy)
330 (32.2) 338 (32.7) Parity ≥2
668 (65.2) 678 (65.6) Previous caesarean section
234 (22.8) 218 (21.1) Previous caesarean sections ≥2
9 (0.9) 10 (1.0) Previous PPH (>500 mL)
44 (4.3) 46 (4.5) Previous pelvic surgery
117.2 (12.2) 117.5 (12.2) Mean preop haemoglobin, g/L (SD)¶
155 (15.2) 147 (14.3) Preop haemoglobin <105 g/L¶
0.351 (0.032) 0.351 (0.032) Mean preop packed cell volume (SD)
689 (67.2) 754 (73.0) Gestational age ≥39 weeks
559 (54.5) 553 (53.5) Infant sex male
160 (15.6) 191 (18.5) Birth weight ≥4.0 kg
413 (40.3) 453 (43.9) Junior obstetrician¶
452 (44.1) 463 (44.9) Junior anaesthetist¶**
11 (1.1) 14 (1.4) Vascular lower segment
92 (9.0) 96 (9.3) Scarring/adhesions
827 (80.7) 793 (76.8) Surgical protocol adherence
Data are number (%) unless stated otherwise. Percentages refer to completed responses. PPH=postpartum haemorrhage. Preop=preoperation.
*Body mass index: weight (kg) divided by the square of height (m).
†Bolus and infusion: n=1029. Bolus only: n=1023.
‡Diabetes, endocrine disease, cardiac disease, hypertension, renal disease, inflammatory bowel disease.
§ Bolus and infusion: n=1031. Bolus only: n=1022.
¶ Junior grade: ≥3 years of specialist training.
** Bolus and infusion: n=1032.
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RESEARCHTable 2| Primary outcomes
Number needed to treat
(95% CI) P value
Adjusted odds ratio*
(95% CI)
Bolus only
No (%)
Bolus and infusion
No (%)
– 0.86 0.98 (0.77 to 1.25) 159/994 (16.0) 158/1007 (15.7) Major obstetric
haemorrhage (blood loss
>1000 mL)†
16 (11 to 32) <0.001 0.61 (0.48 to 0.78) 189/1025 (18.4) 126/1033 (12.2) Additional uterotonic
agent‡
*Odds ratios calculated from models adjusted for centre and previous caesarean section.
†Blood loss calculation: estimated blood volume × (preop PCV – postop PCV)/preop PCV (where PCV=packed cell volume, estimated blood volume=booking
weight (kg) × 85).
‡Oxytocin infusion, oxytocin bolus, misoprostol, 15-methyl-prostaglandin F2α, syntometrine, or ergometrine.
Reprints: http://journals.bmj.com/cgi/reprintform Subscribe: http://resources.bmj.com/bmj/subscribers/how-to-subscribe
BMJ 2011;343:d4661 doi: 10.1136/bmj.d4661 Page 8 of 11
RESEARCHTable 3| Secondary outcomes
P value Odds ratio (95% CI) Bolus only Bolus and infusion
(n=1025 unless otherwise stated) (n=1033 unless otherwise stated)
0.83 4 (−38 to 47)† 583 (489) 587 (505) Mean “calculated” blood loss (mL) (SD)*
0.45 −19 (−65 to 29)† 843 (487) 824 (622) Mean “measured” blood loss (mL) (SD)‡
0.56 0.2 (−0.58 to 1.08)† 11.9 (9.4) 12.1 (9.5) Mean fall in haemoglobin (g/L) (SD)§
0.83 −0.001 (−0.003 to 0.002)† 0.035 (0.029) 0.034 (0.029) Mean fall in packed cell volume (SD)§
0.45 0.93 (0.78 to 1.12) 473 (47.4) 463 (45.8) Postop Hb <105.0 g/L (%)¶
0.25 0.90 (0.74 to 1.08) 330 (33.1) 311 (30.7) Postop Hb <100.0 g/L (%)¶
0.20 0.82 (0.60 to 1.11) 95 (9.6) 80 (7.9) Severe anaemia (≥20% fall in haemoglobin) (%)**
0.63 1.28 (0.48 to 3.46) 7 (0.7) 9 (0.9) Transfusion (%)
0.21 1.16 (0.92 to 1.45) 185 (18.0) 208 (20.1) Side effects to oxytocin (%)††
0.44 0.4 (−0.61 to 1.14)† 30.0 (11.6) 30.4 (11.6) Mean duration of surgery (min) (SD)
0.08 4 (−0.50 to 8.44)† 112.6 (46.8) 116.6 (56.0) Mean length of stay in theatre/recovery (min) (SD)
0.79 1.05 (0.72 to 1.55) 54 (5.3) 57 (5.5) Prolonged hospitalisation (>5 days) (%)
Percentages refer to completed responses.
*Bolus and infusion: n=1007. Bolus only: n=994.
†Absolute difference in mean (95% CI).
‡ Bolus and infusion: n=1020. Bolus only: n=1008.
§ Bolus and infusion: n=1010. Bolus only: n=994.
¶ Bolus and infusion: n=1012. Bolus only: n=997.
** Bolus and infusion: n=1010. Bolus only: n=994.
††Nausea, vomiting, and hypotension.
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RESEARCHTable 4 Subgroup analyses of major obstetric haemorrhage (MOH) and additional uterotonic agent
Parity Non-adherence
to anaesthetic
protocol
Adherence to
anaesthetic
protocol
Senior
obstetrician
Junior
obstetrician ≥2 1 0
No Yes No Yes No Yes No Yes No Yes No Yes No Yes
MOH
183
(85.9)
30
(14.1)
388
(86.0)
63
(14.0)
278
(81.0)
65
(19.0)
11
(84.6)
2 (15.4) 837
(84.3)
156
(15.7)
486
(85.6)
82
(14.4)
363
(82.7)
76
(17.3)
Bolusand
infusion
192
(84.2)
36
(15.8)
353
(84.4)
65
(15.6)
290
(83.3)
58
(16.7)
16
(80.0)
4 (20.0) 819
(84.1)
155
(15.9)
527
(88.1)
71
(11.9)
308
(77.8)
88
(22.2)
Bolus
only
0.86, 0.62 to 1.18, P=0.35 1.59, 0.24 to 10.48, P=0.63 0.57, 0.35 to 0.92, P=0.02 OR, 95%
CI, P
value
Additional uterotonic drug used
192
(88.1)
26
(11.9)
412
(89.6)
48
(10.4)
303
(85.4)
52
(14.6)
11
(84.6)
2 (15.4) 895
(87.8)
124
(12.2)
510
(87.9)
70
(12.1)
397
(87.6)
56
(12.4)
Bolusand
infusion
180
(76.9)
54
(23.1)
362
(83.4)
72
(16.6)
294
(82.4)
63
(17.6)
15
(71.4)
6 (28.6) 821
(81.8)
183
(18.2)
503
(82.2)
109
(17.8)
333
(80.6)
80
(19.4)
Bolus
only
0.76, 0.55 to 1.05, P=0.10 1.40, 0.23 to 8.55, P=0.71 0.95, 0.58 to 1.56, P=0.84 OR, 95%
CI, P
value
Data are number (%) unless specified otherwise. OR=odds ratio. 95% CI=95% confidence intervals.
Reprints: http://journals.bmj.com/cgi/reprintform Subscribe: http://resources.bmj.com/bmj/subscribers/how-to-subscribe
BMJ 2011;343:d4661 doi: 10.1136/bmj.d4661 Page 10 of 11
RESEARCHFigure
Fig 1 Summary of participant flow through trial
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